Practical guidance on NOACs and safety: How to deal with challenging situations in AF
Latest frontiers in anticoagulation therapy (3/4)
Prof. John Eikelboom discusses the indications for reversal of anticoagulation and results of trials with the available reversal agents.
Video navigation menu
- Bleeding management principles 01:12
- Indications for specific reversal 02:15
- REVERSE-AD trial: dabigatran reversal with idarucizumab 03:40
- ANNEXA-4 trial: Factor Xa reversal with andexanet alfa 06:28
- How to reduce bleeding risk? 09:39
- What is the ratio of bleeding vs surgery in clinical practice for reversal of anticoagulation? 12:57
This educational video is part of a series called Latest frontiers in anticoagulation therapy and recorded during an EBAC accredited session held on January 12, 2018
The overall objective is to provide an expert perspective on appropriate use of NOACs in clinical practice
Educational objectives of the CME session were to:
- Review and summarize recent clinical evidence on non-vitamin K antagonist anticoagulants (NOACS) in patients with atrial fibrillation and trombosis
- Provide clinical guidance, based on novel insights on safety and tolerability, on management of patients in challenging situations
- Provide an expert perspective on the appropriate use of NOACs in clinical practice
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Prof. John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada
Prof. Saskia Middeldorp, internist, professor of Vascular Medicine at the Academic Medical Center Amsterdam, The Netherlands
Dr. Hanna Pohjantähti-Maaroos, Heart Center, Kuopio University Hospital, Finland
Funding to produce this educational video series was provided by an unrestricted educational grant from Boehringer Ingelheim.